Showing 1321-1330 of 18577 results for "".
Living Well with IBD: Proactive Health Maintenance Strategies
https://reachmd.com/programs/gi-insights/living-well-with-ibd-proactive-health-maintenance-strategies/18013/Join us as we explore how we can optimize the health of our patients with IBD using strategies that go beyond the treatment of symptoms and disease.Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
https://reachmd.com/programs/medical-industry-feature/igan-pathogenesis-april-4-hit-process-patient-case-study/29535/In IgA nephropathy (IgAN), patients have a high burden of kidney disease at diagnosis, often presenting with chronic kidney disease stage ≥3.1-3 Early recognition is critical for management. That’s why Dr. Abby Yancey and Dr. Kartik Kalra explore IgAN’s underlying pathogenesis, heterogeneity in initShifting the Script: How Inner Dialogue Influences Psoriasis Progress
https://reachmd.com/programs/frontlines-psoriasis/inner-dialogue-psoriasis-progress/39949/A patient’s inner dialogue—especially negative self-talk—can influence their perception of disease, adherence to treatment, and emotional wellbeing. Ryan Quigley sits down with Dr. Michael Greenberg, a dermatologist at the Illinois Dermatology Institute, as he shares observations from his own practiGenetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
https://reachmd.com/programs/clinicians-roundtable/genetic-testing-in-pediatrics-identifying-neurodevelopmental-disorders-early/37129/Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting theIgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment
https://reachmd.com/programs/clinicians-roundtable/iga-nephropathy-care-a-shift-toward-proactive-targeted-treatment/33209/Delayed diagnosis and limited treatment options have historically been barriers to optimal management of IgA nephropathy (IgAN), but that paradigm may be shifting. A paper published in Kidney International in April 2025 points out that significant nephron loss often occurs before diagnosis, making eSupplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
https://reachmd.com/programs/clinicians-roundtable/supplement-use-for-colorectal-cancer-prevention-insights-from-nccn-guidelines/36406/According to the NCCN Guidelines for Colorectal Cancer Screening, there is mixed evidence around the impact of vitamin D, calcium, folate, and aspirin on colorectal cancer risk. Join Dr. Reid Ness as he discusses considerations for recommending these supplements based on patient-specific factors. DGene Therapy Safety in DMD: How to Identify Common Immune Reactions
https://reachmd.com/programs/neurofrontiers/gene-therapy-safety-in-dmd-how-to-identify-common-immune-reactions/35681/Gene therapy for Duchenne muscular dystrophy (DMD) introduces a micro-dystrophin transgene to support improved protein production, but it’s not without serious risks, including myocarditis, hepatic inflammation, and myositis. Here to help raise awareness of the common immune complications associatedNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/new-frontiers-in-the-imaging-and-treatment-of-advanced-prostate-cancer/32221/From PSMA imaging to precision medicine strategies based on molecular drivers, novel diagnostics and therapies are reshaping the way we care for men with advanced prostate cancer. But despite these advancements, certain challenges and unmet needs remain. Joining Dr. Wayne Kuang to talk about these eUnraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
https://reachmd.com/programs/neurofrontiers/unraveling-the-mechanism-how-ocrelizumab-impacts-cortical-lesions-in-ms/32367/While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succe